Telmisartan attenuates progression of steatohepatitis in mice: Role of hepatic macrophage infiltration and effects on adipose tissue

Liver International

Volumn 29, Issue 7, 2009, Pages 988-996

  Kudo, Hiroshi ^a   Yata, Yutaka ^a,b   Takahara, Terumi ^a   Kawai, Kengo ^a   Nakayama, Yasuhiro ^a   Kanayama, Masami ^a   Oya, Takeshi ^a   Morita, Seiichi ^a   Sasahara, Masakiyo ^a   Mann, Derek A ^c   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CC chemokine receptor 2; Macrophage; Monocyte chemoattractant protein 1; Non alcoholic steatohepatitis; Telmisartan

Indexed keywords

ADIPONECTIN; CHEMOKINE RECEPTOR CCR2; CHOLINE; COLLAGEN TYPE 1; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; METHIONINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CELL SIZE; CONTROLLED STUDY; DRUG EFFICACY; FIBROGENESIS; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; LIPID DIET; LIPID LIVER LEVEL; LIVER WEIGHT; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

ADIPOCYTES; ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CELL LINE; CELL SIZE; CHEMOKINE CCL2; CHOLINE DEFICIENCY; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRINKING; EATING; FATTY LIVER; INTRA-ABDOMINAL FAT; LIVER; LIVER CIRRHOSIS; MACROPHAGES; MALE; METHIONINE; MICE; MICE, INBRED C57BL; ORGAN SIZE; OXIDATIVE STRESS; RECEPTORS, CCR2; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 67650480409     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02006.x     Document Type: Article

References (34)

1. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989; 20: 594-8.
2. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insuline resistance syndrome. Hepatology 2002; 35: 373-9.
3. Powell EE, Cooksley W, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
4. Yoshiji H, Kuriyama S, Yoshiji J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
5. Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999; 277: 920-6.
6. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
7. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
8. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
10. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
11. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 1998; 18: 1983-91.
12. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
13. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
14. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
15. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807.
16. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
17. Qiang L, Wang H, Farmer SR. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 2007; 27: 4698-707.
18. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-6.
19. Weisberg SP, Mccann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
20. Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004; 94: 1203-10.
21. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-24.
22. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.
23. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
24. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
25. Pessayre D, Berson A, Fromntry B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
26. Osmundsen H, Bremer J, Pedersen JI. Metabolic aspects of peroxisomal beta-oxidation. Biochim Biophys Acta 1991; 1085: 141-58.
27. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004; 172: 2522-9.
28. Fox ES, Brower JS, Bellezzo JM, Leingang KA. N-acetylcysteine and alpha-tocopherol reverse the inflammatory response in activated rat Kupffer cells. J Immunol 1997; 158: 5418-23.
29. Tanaka T, Fukunaga Y, Itoh H, et al. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 2005; 508: 255-65.
30. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 5: 1375-81.
31. Fijita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007; 52: 3455-64.
32. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2007; 364: 801-7.
33. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-61.
34. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-54.